Antisense 'proof-of-concept' study demonstrates activity of ATL1101 in psoriasis patients
05 October, 2005 by Helen SchullerAntisense Therapeutics (ASX:ANP) has produced positive results from a 'proof-of-concept' study of its second generation antisense drug ATL1101 to suppress the insulin-like growth factor-1 receptor (IGF-1R), which is under development as a cream for the topical treatment of the skin disorder psoriasis.
Citrofresh quashes HIV orange cure talk
29 September, 2005 by Staff WritersGeelong-based disinfectant maker Citrofresh International (ASX:CTF), which caused a stock frenzy with news of a cure-all ingredient found in oranges, has dashed investors' hopes it had a vaccine against HIV, SARS, flu and the common cold.
Acrux granted four US patents, licensee meets with FDA
27 September, 2005 by Ruth BeranAcrux (ASX:ACR) has been granted four more US patents relating to its transdermal drug delivery technology.
Phosphagenics claims promising insulin results
21 September, 2005 by Helen SchullerMelbourne's Phosphagenics (ASX:POH) has successfully delivered insulin through the skin of animals using its patented transdermal drug delivery system TPM-01.
Psiron puts back cancer trial results
20 September, 2005 by Graeme O'NeillSydney oncology therapy developer Psiron (ASX:PSX) has announced a delay in reporting the results of its first phase I clinical trial of its cancer-slaying CVA 21 viral therapy in melanoma patients because of delays in access to supplies of the virus.
Russian approval granted for Norwood EyeCare products
16 September, 2005 by Helen SchullerNorwood Devices, a division of medical technologies group Norwood Abbey (ASX:NAL) has received approval from the Russian Ministry of Health to import and sell the Norwood EyeCare Epi-LASIK system.
SSH aims to raise $4.3m for Bio-Layer
16 September, 2005 by Ruth BeranSydney-based SSH Medical (ASX:SSH) has started accepting applications for subscriptions to raise approximately $4.3 million to provide working capital for material science company Bio-Layer, which SSH is acquiring.
First enrolment for Pharmaxis Aridol COPD study
16 September, 2005 by Helen SchullerDrug developer Pharmaxis (ASX:PXS) has enrolled its first patient for the phase II clinical trial to assess the ability of Aridol to predict the usefulness of inhaled corticosteroids as a treatment of chronic obstructive pulmonary disease (COPD).
Novogen drug reduces cardiovascular risk, subsidiary to list on NASDAQ
14 September, 2005 by Ruth BeranBiopharmaceutical company Novogen's (ASX:NRT) cardiovascular drug trans NV-04 has shown a significant reduction in blood pressure and reduced arterial stiffness in a Phase Ib clinical trial.
Grunt work over, Starpharma looks to VivaGel future
09 September, 2005 by Helen SchullerContinuing development of its lead product VivaGel has boosted Starpharma's (ASX:SPL) 2004-05 losses to $5.5 million, up 38 per cent from the previous year.
Indian orders for Panbio JE diagnostic
07 September, 2005 by Ruth BeranMedical diagnostics company Panbio's (ASX:PBO) new assay for Japanese encephalitis (JE), released for sale just two days ago, has received immediate interest and has been shipped to India where a JE outbreak has resulted in 1145 reported cases, including 296 deaths.
Progen flush as PI-88 trials continue
06 September, 2005 by Helen SchullerBrisbane cancer drug developer Progen Industries (ASX:PGL) has reported a strong cash position of AUD$23.43 million, up 64 per cent on last year for the year ended 30 June 2005, as it continues to trial its lead anti-cancer compound.
Solbec's Coramsine found safe and tolerable
05 September, 2005 by Ruth BeranSolbec Pharmaceuticals' (ASX:SBP) devil's apple-derived drug Coramsine (SBP002) has met the primary endpoint of safety and tolerability for the two-hour infusion cohort of its single agent phase I clinical trial for advanced solid tumours.
Bionomics allowed US epilepsy gene patent
02 September, 2005 by Ruth BeranSouth Australian genomics company Bionomics (ASX:BNO) has received a notice of allowance for a US patent, forming part of the company's patent portfolio covering a diagnostic test for severe forms of childhood epilepsy.
Peter Mac tests tumour-cell zapper
02 September, 2005 by Graeme O'NeillResearchers at Melbourne's Peter MacCallum Cancer Centre have begun testing a high-precision, antibody-mediated system to deliver short-range radionuclides to cancerous cells.
